Interpreting technetium-99m pyrophosphate cardiac scans to diagnose transthyretin cardiac amyloidosis: Need for due diligence

J Nucl Cardiol. 2021 Aug;28(4):1798-1801. doi: 10.1007/s12350-020-02181-6. Epub 2020 May 10.

Authors

Brian Butera¹, Diane Klingler¹, James K Mccord¹, Karthik Ananthasubramaniam²

Affiliations

¹ Heart and Vascular Institute, Henry Ford West Bloomfield Hospital, 6777 West Maple, West Bloomfield, MI, 48322, USA.
² Heart and Vascular Institute, Henry Ford West Bloomfield Hospital, 6777 West Maple, West Bloomfield, MI, 48322, USA. kananth1@hfhs.org.

PMID: 32390109
DOI: 10.1007/s12350-020-02181-6

No abstract available

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Amyloid Neuropathies, Familial / diagnostic imaging*
Cardiomyopathies / diagnostic imaging*
Diagnostic Errors / prevention & control*
Humans
Male
Radiopharmaceuticals*
Technetium Tc 99m Pyrophosphate*
Tomography, Emission-Computed, Single-Photon*

Substances

Radiopharmaceuticals
Technetium Tc 99m Pyrophosphate

Supplementary concepts

Amyloidosis, Hereditary, Transthyretin-Related